PTJ
PCVX icon

Paul Tudor Jones’s Vaxcyte PCVX Stock Holding History

Paul Tudor Jones’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Buy
32,100
+12,100
+61% +$657K ﹤0.01% 1990
2026
Q1 		$1.16M Buy
+20,000
New +$1.09M ﹤0.01% 2254
2025
Q4 		– Sell
-10,500
Closed -$378K – 3917
2025
Q3 		$378K Sell
10,500
-500
-5% -$16.6K ﹤0.01% 2851
2025
Q2 		$358K Buy
+11,000
New +$361K ﹤0.01% 2788

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Paul Tudor Jones's PCVX Position: Q4 2025 in Review

Paul Tudor Jones sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 73,035 shares — an estimated $2.63M sold.

Paul Tudor Jones first reported a position in PCVX in Q1 2023 and held it in 4 quarters. The position peaked at $2.63M in Q3 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • Paul Tudor Jones reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • Paul Tudor Jones sold 73,035 Vaxcyte shares in Q4 2025, an estimated $2.63M.
  • Paul Tudor Jones first reported a position in Vaxcyte in Q1 2023 and held it in 4 quarters.
  • Paul Tudor Jones's Vaxcyte position peaked at $2.63M in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Tudor Investment Corp's 13F filing for Q4 2025, filed 17 Feb 2026.